Hledání v detailu akcií
Top akcie
NázevNávštěvy
31 150
1 248
1 134
1 034
932
677
543
518
373
365
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,38
KB-1,24
PKN109,35106,2-0,05
Msft2,55
IBM-0,97
DCX70,9570,980,17
PFE2,03
16.12.2017 2:10:00
Indexy online
AD Index online
select
AD Index online
 

  • 15.12.2017
Macrogenics (NASDAQ Cons)
Závěr k 15.12.2017 Změna (%) Změna (USD) Objem obchodů (ks)
19,27 1,31 0,25 488 410
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 16.12.2017
Popis společnosti
Obecné informace
Název společnostiMacroGenics Inc
TickerMGNX
Kmenové akcie:Ordinary Shares
RICMGNX.O
ISINUS5560991094
Poslední známé roční výsledky31.12.2016
Poslední známé čtvrtletní výsledky30.9.2017
Počet zaměstnanců k 31.12.2016 318
Akcie v oběhu k 3.11.2017 36 822 710
Počet akcionářů k 31.12.2016 89
MěnaUSD
Kontaktní informace
Ulice9704 Medical Center Dr
MěstoROCKVILLE
PSČ20850-3343
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon13 012 515 172
Fax13012515321

Business Summary: MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies. It has a pipeline of product candidates in human clinical testing, primarily as treatments for different types of cancers, which are created using its technology platforms. Its clinical product candidate, margetuximab, has been enhanced using its Fc Optimization platform. The Company is also developing several product candidates targeting B7-H3, a protein in the B7 family of immune regulator proteins. The Company's product candidates also include enoblituzumab and MGD009, MGC018, MGD006 (flotetuzumab), MGD007, MGD011 (duvortuxizumab), PF-06671008 and MGD010.
Financial Summary: BRIEF: For the nine months ended 30 September 2017, MacroGenics Inc revenues decreased 94% to $5.4M. Net loss increased from $23.7M to $125.4M. Revenues reflect Revenue from collaborative agreements decrease of 96% to $3.4M, Revenue from government agreements decrease of 55% to $1.9M. Higher net loss reflects Research&development-Bal Val increase of 18% to $102.7M (expense).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Bio Therapeutic Drugs
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
SICPharmaceutical Preparations
SICPharmaceutical Preparations
SICCommercial Physical Research



  • Poslední aktualizace: 16.12.2017
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Independent Chairman of the BoardPaulo Costa66
President, Chief Executive Officer, DirectorScott Koenig64
Chief Financial Officer, Senior Vice President, SecretaryJames Karrels50
Senior Vice President - Research, Chief Scientific OfficerEzio Bonvini6314.9.2016
Senior Vice President, General CounselAtul Saran4330.4.201430.4.2014
Senior Vice President - Business Development and Portfolio Management and Chief Business OfficerEric Risser44
Senior Vice President - Bio Pharmaceutical Development and ManufacturingThomas Spitznagel501.1.2013
Senior Vice President - Clinical Development and Chief Medical OfficerJon Wigginton551.3.2016
Vice President, Controller, TreasurerLynn Cilinski59